Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

1 mg semaglutide, insulin degludec, or insulin glargine for 40 or 52 weeks. In this post hoc analysis, the researchers assessed patients (N=6246) with T2D for the time of maintaining glycated ...

"We are entering a new era of obesity care where patients want individualized treatment plans that address their needs and provide choices, including oral formulations," said Anna Windle, PhD ...

PLAINSBORO, N.J., May 2, 2025 /PRNewswire/ -- Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an ...

OASIS 4 included a 64-week treatment period including a 12-week dose escalation, and a 7-week off-treatment follow-up period. In total, 307 participants were randomized 2:1 ratio to once-daily oral ...

25 mg oral formulation of Wegovy ® (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major ...

"We are entering a new era of obesity care where patients want individualized treatment plans that address their needs and provide choices, including oral formulations," said Anna Windle, PhD, Senior ...

Novo Nordisk (NVO) announced Friday that the U.S. Food and Drug Administration (FDA) accepted its marketing application for ...

It’s also used off-label for weight loss. Its sister drug, Wegovy — which contains a higher dose of the same active ingredient, semaglutide — is approved for chronic weight management in ...